Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke

Neuroscience Bulletin

Volumn 25, Issue 6, 2009, Pages 383-390

  Guo, Jian Jun ^a   Xu, En ^a   Lin, Qing Yuan ^a   Zeng, Guo Ling ^a   Xie, Hai Feng ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Aspirin; Cilostazol; Ischemic; Magnetic resonance angiography; Stroke; Transcranial doppler ultrasonography

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAMIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BLOOD FLOW VELOCITY; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; TREATMENT RESPONSE; VAGINA BLEEDING;

ASPIRIN; BLOOD FLOW VELOCITY; BRAIN; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRACRANIAL HEMORRHAGES; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STROKE; TETRAZOLES; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 72349091456     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-009-6192-2     Document Type: Article

References (17)

1. A. Szczeklik J. Musial A. Undas M. Sanak R. Nizankowski 2005 Aspirin resistance Pharmacol Rep 57 Suppl 33 41 16415485
2. J. He P.K. Whelton B. Vu M.J. Klag 1998 Aspirin and risk of hemorrhage stroke: a meta-analysis of randomized controlled trials JAMA 280 22 1930 1935 10.1001/jama.280.22.1930 1:CAS:528:DyaK1MXhtFyg 9851479
3. F. Gotoh H. Tohgi S. Hirai 2000 Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of ischemic stroke Cerebrovasc Dis 9 4 147 157 10.1053/jscd.2000.7216 (Pubitemid 30480490)
4. M. Matsumoto 2005 Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study Atheroscler Suppl 6 4 33 40 10.1016/j.atherosclerosissup.2005.09.003 1:CAS:528:DC%2BD28Xhslyrsrw%3D 16275125 (Pubitemid 43261538)
5. S.U. Kwon Y.J. Cho J.S. Koo H.J. Bae Y.S. Lee K.S. Hong, et al. 2005 Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis Stroke 36 4 782 786 10.1161/01.STR.0000157667.06542.b7 1:CAS:528:DC%2BD2MXislait7Y%3D 15746463
6. R.W. Becker E. Lusis R.L. Sohn R.A. Kline 2005 Effects of cilostazol on human venous smooth muscle Ann Vasc Surg 19 3 393 397 10.1007/s10016-005-0012-6 15818459 (Pubitemid 40884095)
7. T. Wang M.B. Elam W.P. Forbes J. Zhong K. Nakajima 2003 Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication Atherosclerosis 171 2 337 342 10.1016/j. atherosclerosis.2003.08.017 1:CAS:528:DC%2BD3sXptlyntb0%3D 14644405 (Pubitemid 37492883)
8. J.H. Lee S.Y. Park Y.W. Shin K.W. Hong C.D. Kim S.M. Sung, et al. 2006 Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion Brain Res 1082 1 182 191 10.1016/j.brainres.2006.01.088 1:CAS:528: DC%2BD28XjtFaitr4%3D 16516167
9. K. Schror 2002 The pharmacology of cilostazol Diabetes Obes Metab 4 Suppl2 S14 S19 10.1046/j.1463-1326.2002.0040s2s14.x 1:CAS:528: DC%2BD38XjvFGitLg%3D 12180353 (Pubitemid 41185670)
10. U. Sliwka C. Klotzsch O. Popescu K. Brandt P. Schmidt P. Berlit, et al. 1997 Do chronic middle cerebral artery stenoses represent an embolic focus? A multirange transcranial Doppler study Stroke 28 7 1324 1327 1:STN:280: DyaK2szntFCmsA%3D%3D 9227677
11. J. He D. Gu X. Wu K. Reynolds X. Duan C. Yao, et al. 2005 Major causes of death among men and women in China N Engl J Med 353 1124 1134 10.1056/NEJMsa050467 1:CAS:528:DC%2BD2MXhtVWhsbnK 16162883 (Pubitemid 41317435)
12. Y. Huang Y. Cheng J. Wu Y. Li E. Xu Z. Hong, et al. 2008 Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study Lancet Neurol 7 6 494 499 10.1016/S1474-4422(08)70094-2 1:CAS:528:DC%2BD1cXntlSjtLo%3D 18456558
13. Y. Yashiro T. Ohhashi 2002 Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles Jpn J Physiol 52 5 471 477 10.2170/jjphysiol.52.471 1:CAS:528:DC%2BD3sXhtlCqsb4%3D 12533252 (Pubitemid 36205591)
14. K. Tanaka F. Gotoh Y. Fukuuchi T. Amano D. Uematsu J. Kawamura, et al. 1989 Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia Stroke 20 5 668 673 1:CAS:528:DyaL1MXktFOnsb8%3D 2718208
15. F. Honda H. Imai M. Ishikawa C. Kubota T. Shimizu M. Fukunaga, et al. 2006 Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia Stroke 37 1 223 228 10.1161/01.STR.0000196977.76702.6d 1:CAS:528:DC%2BD2MXhtlagsb%2FM 16339464 (Pubitemid 43732075)
16. T. Shinoda-Tagawa Y. Yamasaki S. Yoshida Y. Kajimoto T. Tsujino N. Hakui, et al. 2002 A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes Diabetologia 45 2 188 194 10.1007/s00125-001-0740-2 1:CAS:528:DC%2BD38Xhs1enu74%3D 11935149 (Pubitemid 34208380)
17. N. Komas C. Lugnier R. Andriantsitohaina J.C. Stoclet 1991 Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric artery Eur J Pharmacol 208 1 85 87 10.1016/0922-4106(91)90056-N 1:CAS:528:DyaK3MXmslCisLY%3D 1657622